DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

* Stratification by treatment experience

• SOF/VEL: 400/100 mg 1 tablet QD
• Patients enrolled in 29 sites in Spain

Primary endpoint

• SVR₁₂ (HCV < 15 IU/mL)

Baseline characteristics

Primary Endpoint (SVR₁₂)

NS5A RAS: 19% in SOF/VEL (SVR₁₂ : 84%), 22% in SOF/VEL + RBV (SVR₁₂ : 96%)
Patients with Y93H: N = 4 in SOF/VEL (SVR₁₂ : 50%), N = 9 in SOF/VEL + RBV (SVR₁₂ : 88.9%)

Primary Endpoint (SVR₁₂) by prior treatment

Adverse events (AE) and laboratory abnormalities, N (%)

Conclusion

• High rates of SVR₁₂ were observed with 12 weeks of SOF/VEL ± RBV in patients with GT3 and compensated cirrhosis
• Adding RBV reduced the relapse rate from 5% to 2%
• Treatment was well-tolerated